Orchard Therapeutics plc
ORTXDelisted Jan 24, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001748907
Orchard Therapeutics plc was delisted on Jan 24, 2024; its insiders filed their last Form 4 on Jan 24, 2024; 47 institutions reported holding it in 13F filings for Q4 2023, worth $122.0M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 47
- Q4 2023, +16 vs. previous quarter
- 13F value
- $122.0M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2022
- $22.7M
- +1,252.5% year over year
- Net income, FY2022
- -$150.7M
- No comparable prior period
- Free cash flow, FY2022
- -$82.5M
- No comparable prior period
- Revenue, Q3 FY2023
- $6.30M
- +9.1% year over year
Revenue flow, FY2022
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2022: $150.7M (665.0% of revenue).
Superinvestors holding ORTX, Q4 2023
Go to the superinvestors tabNo superinvestor reported holding ORTX at the end of Q4 2023.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Orchard Therapeutics plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Gaspar BobbyChief Executive Officer | PPurchase | +15.0K | $0.74 | +$11.1K | +4.3%366.2K after | |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Thomas Frank ESee Remarks | PPurchase | +10.0K | $0.75 | +$7.50K | +23.8%52.1K after |
Top 10 13F holders, Q4 2023
See all 47 holdersThe largest institutional positions in Orchard Therapeutics plc at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 2,041,670 | $33.6M | 1.18% | 00.0% | Unchanged |
| Beryl Capital Management LLC | 1,561,499 | $25.7M | 14.11% | +1,561,499 | New |
| Federated Hermes, Inc. | 869,327 | $14.3M | 0.04% | 00.0% | Unchanged |
| LMR Partners LLP | 332,223 | $5.47M | 0.14% | +332,223 | New |
| Tudor Investment Corp Et Al | 300,000 | $4.93M | 0.07% | +300,000 | New |
| Millennium Management LLC | 238,852 | $3.93M | 0.00% | +238,852 | New |
| Gabelli Funds LLC | 224,250 | $3.69M | 0.03% | +224,250 | New |
| Renaissance Technologies LLC | 196,918 | $3.24M | 0.01% | +82,100+71.5% | Added |
| Gabelli & Co Investment Advisers, Inc. | 192,650 | $3.17M | 0.59% | +192,650 | New |
| Qube Research & Technologies Ltd | 172,579 | $2.84M | 0.01% | +172,576+5,752,533.3% | Added |